Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China

Serapha Bio Goes Public via Reverse Merger with Boundless Bio

Private biotech Serapha Bio is going public via a reverse merger with Boundless Bio, bringing $230 million in starting funds and a gene editing asset from China. The $230 million includes a $138 million placement from a prior Series A round and $92 million in pre-closing private investments. The combined entity, which will retain Serapha's name and ticker AATD, will focus on developing the investigational gene editor SERP-01 for severe alpha-1 antitrypsin deficiency (AATD). Serapha also licensed SERP-01 globally outside Greater China from YolTech Therapeutics. The merger is expected to close in the fourth quarter, with Serapha's pre-merger stockholders owning 96.3% of the new company.

• Serapha Bio is entering the public market through a reverse merger with Boundless Bio, securing $230 million in funding. This capital comprises a $138 million Series A round and an additional $92 million in pre-closing private investments. Upon completion in Q4, Serapha's pre-merger stockholders will hold approximately 96.3% of the combined entity, which will trade under the ticker AATD.
• The core focus of the newly combined company will be the development of SERP-01, an investigational gene editor licensed from Shanghai-based YolTech Therapeutics. Serapha secured worldwide rights to SERP-01 outside Greater China through a deal involving an undisclosed upfront sum and a minority equity stake in Serapha.
• SERP-01 is designed to correct a mutation in the SERPINA1 gene, targeting severe alpha-1 antitrypsin deficiency (AATD). AATD is a hereditary condition caused by misfolded SERPINA1 proteins leading to organ damage, particularly in the lungs and liver. The press release notes that other companies like Beam Therapeutics and Wave Life Sciences are also pursuing gene editing approaches for AATD.

Why Serapha's Gene Editor Targets AATD's Unmet Needs

Alpha-1 antitrypsin deficiency (AATD) remains substantially underdiagnosed and undertreated, with current standard-of-care augmentation therapy providing only partial, burdensome relief rather than a curative solution. Despite decades of clinical use, augmentation therapy cannot be formally recommended due to insufficient evidence of clinical benefit, and the field continues to grapple with fundamental gaps in disease monitoring, patient stratification, and trial methodology.

• Unproven clinical efficacy and high treatment burden: Augmentation therapy lacks robust evidence of clinical benefit and requires lifelong intravenous administration—at best preserving the level of lung damage present at diagnosis rather than reversing it—while carrying substantial associated costs.

• Trial design and recruitment complexities: The low prevalence and slow progression of AATD make it impractical to conduct adequately powered studies measuring lung function decline. Registrational trials face additional hurdles including subject identification, logistical challenges across geographically dispersed sites, poorly defined endpoints, and direct competition from commercially available augmentation therapy in many countries.

• Highly variable disease progression: Registry data demonstrate marked inter-patient variability in lung disease trajectory, driven by differences in patient acquisition and recognized risk factors. This variability complicates both prognosis and treatment decision-making, necessitating an individualized approach in experienced specialist centres.

• Inability to identify rapid decliners early: Serial lung function monitoring over 18 months cannot reliably identify patients with rapidly declining lung function—the positive predictive value for rapid decline at 18 months versus 3 years of follow-up was only 50.0%. There is an urgent need for validated biomarkers capable of flagging these high-risk patients earlier, particularly in mild disease.

• Unresolved questions around augmentation therapy optimisation: The effects of augmentation therapy on key outcomes—including exacerbation frequency and duration, quality of life, lung function decline, and mortality—remain unclear. Questions regarding dose optimisation and route of administration are still actively debated, with individual pharmacokinetic profiling proposed as a potential path toward more tailored regimens.

• Expanding mechanistic knowledge not yet clinically actionable: Although understanding of AAT's immunomodulatory, anti-infective, and anti-inflammatory properties is growing, this knowledge has not yet translated into improved ability to predict patient outcomes or guide therapeutic stratification.

Unpacking the Genetic Drivers of Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency (AATD) is an autosomal codominant disorder arising from mutations in the SERPINA1 gene, which encodes the serine protease inhibitor alpha-1 antitrypsin (AAT). The gene is highly polymorphic, harboring over 120 known variants, though the vast majority of clinically significant disease is attributable to the Z and S alleles — single-nucleotide variations (SNVs) producing amino acid substitutions E342K and E264V, respectively. The ZZ genotype is the most common genotype associated with pulmonary disease, and compound heterozygosity (e.g., PI*SZ, PI*MZ) also confers meaningful clinical risk. Beyond these common variants, next-generation sequencing continues to uncover rare and novel pathogenic variants including splice variants, base pair deletions, stop codon insertions, and additional SNVs — many of which appear to exert their deleterious effects through disruption of the packed hydrophobic core of the AAT protein. Disease manifests when deleterious mutations are present on both alleles, resulting in either reduced AAT secretion, dysfunctional protein, or both.

The central molecular event in AATD pathogenesis is misfolding of the Z-AAT protein during biogenesis within the endoplasmic reticulum (ER). Approximately 85% of Z-AAT molecules are retained within hepatocytes rather than secreted, with a proportion adopting an aberrant polymerized conformation within the ER. These intracellular polymers trigger a cascade of hepatocellular injury encompassing ER stress, mitochondrial depolarization, caspase activation, and dysregulation of autophagy and redox pathways. While most retained Z-AAT is directed toward ER-associated degradation (ERAD) or autophagy — processes in which ER-resident chaperones such as ERdj3 play quality-control roles — molecules that escape clearance accumulate as inclusion bodies, driving a chronic cycle of hepatocyte death, stellate cell activation, fibrosis, and, in some patients, progression to cirrhosis or hepatocellular carcinoma. In the lung, the resulting deficiency of circulating AAT leaves pulmonary tissue vulnerable to unopposed neutrophil elastase activity. Emerging evidence further implicates cell-intrinsic mechanisms in alveolar disease: type 2 alveolar epithelial cells (AT2s) heterogeneously retain Z-AAT and exhibit transcriptomic disease signatures characterized by innate immune and inflammatory signaling, NF-κB activation, ER stress, and activation of the PERK–eIF2α axis. A subpopulation of these cells adopts markers of an alveolar basal intermediate (ABI) state, and murine models of AT2-specific Z-AAT expression demonstrate increased susceptibility to elastase-induced emphysema, providing functional evidence for AT2-intrinsic contributions to lung pathology.

At a systems level, AATD represents a profound disruption of the proteostasis network — the >2,000-component cellular machinery governing protein synthesis, folding, trafficking, and degradation. Z-AAT aggregates activate extracellular folding stress pathways, while dysregulation of Nrf2 signaling and misprocessing via histone acetyltransferase (HAT)/histone deacetylase (HDAC) pathways further amplify airways stress responses. In neutrophils, Z-AAT misfolding within the ER induces ER stress, upregulates proapoptotic signals including TNF-α, and increases apoptosis nearly two-fold in PiZZ individuals compared to healthy controls — impairing bacterial killing capacity. RNA-seq analyses of blood neutrophils from AATD individuals reveal transcriptional dysregulation across intracellular signaling, immune response regulation, and metabolic adaptation, including upregulation of interferon, pattern recognition receptor, and cytokine-mediated pathways that may create a self-amplifying inflammatory loop. Collectively, these mechanisms establish AATD as a disease of both loss-of-function (protease–antiprotease imbalance) and toxic gain-of-function (proteotoxic and inflammatory sequelae of misfolded protein accumulation), with therapeutic implications spanning autophagy enhancement, RNAi-mediated hepatic AAT silencing, and targeted proteostasis modulation.